Navigation Links
Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab

imumab. The primary endpoint of the study was to investigate the safety and clinical activity of various doses of ipilimumab. The study enrolled 88 patients with unresectable stage III or stage IV malignant melanoma in three cohorts receiving varying doses and regimens. Analysis of the data demonstrated:

    - Overall disease control - defined as objective responses (complete and

      partial) and stable disease - achieved in 19% (17/88) of patients.

      - In the cohort of 23 patients who were treated at 10 mg/kg, disease

        control was achieved in 39% (9/23), which lasted six months or longer

        in nearly all patients (8/9).

    - Duration of disease stabilization or response exceeded six months in 15%

      (13/88) of patients.  The longest effect observed (stable disease) is

      ongoing for more than a year.

Adverse events reported in this study were consistent with those immune- related adverse events (irAEs) results in other clinical trials of ipilimumab (diarrhea, rash, adrenal insufficiency, elevated liver enzymes). In this study, the overall incidence of irAEs was 72% (63/88). All patients who achieved a response (complete or partial responses) and most patients who achieved stable disease (12/13) also reported an irAE - primarily grade 1 or 2 with the exception of grade 3 diarrhea (1/88), adrenal insufficiency (1/88) and liver abnormalities (1/88) in three patients with stable disease. Twenty- eight percent (25/88) of patients reported serious adverse events (SAEs) regardless of causality, nine of which were ipilimumab-related, but not dose dependent. Most events were reversible without sequelae.

(Abstract #8525) Analysis of data aggregated from six Phase I and II trials, presented by Omid Hamid, MD, an investigator at The Angeles Clinic and Research Institute in Los Angeles, California, showed durable objective responses and stable disease in some patients who received varying doses of ipilimumab (0.1 up to
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
2. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
3. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Study Demonstrated Rozerem (ramelteon) Does Not Affect Middle-of-the-Night Balance in Older Adults with Insomnia
6. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
7. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
8. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
9. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
10. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
11. 12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)
Post Your Comments:
(Date:9/16/2014)... 16, 2014 The Pulmonary Fibrosis Foundation (PFF) ... more than 1,100 patients and families suffering from pulmonary ... (FDA) for the Patient-Focused Drug Development Meeting for Idiopathic ... FDA initiative to seek patient input in order to ... "We applaud the FDA for focusing its ...
(Date:9/16/2014)... 2014 Chindex International, Inc. ("Chindex" or the ... a special meeting of stockholders held today, the Company,s ... Agreement") by and among the Company, Healthy Harmony Holdings, ... Parent is an affiliate of TPG, Shanghai Fosun Pharmaceutical ... , the CEO of the Company. The ...
(Date:9/16/2014)... /PRNewswire-iReach/ -- Dan York has been named ... the RTD ® Advanced Wound Care Dressing, as ... presence in the U.S. Under York,s leadership, GWM Products, ... sales representatives in new sales territories that will complement ... up to 20 sales representatives in major metropolitan areas ...
Breaking Medicine Technology:PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 2PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 3PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 4Chindex Stockholders Approve Merger 2Chindex Stockholders Approve Merger 3GWM Products, LLC, announces U.S. market expansion. Dan York added as Director of Sales as part of nationwide growth initiative. 2
... studies including a pivotal Phase III trial in patients,with ... tablets will be presented at the Annual,Meeting of the ... June 1 - 5, 2007. , On this occasion ... on June 4, 2007. Starting at around 2:00 p.m. ...
... of Eisai's,Commitment to Oncology, WOODCLIFF LAKE, N.J., May ... abstracts covering clinical data about,their oncology pipeline compounds ... of Clinical Oncology (ASCO),annual meeting. ASCO takes place ... reveal a growing and diverse oncology clinical,development program ...
Cached Medicine Technology:Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 2Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 3Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting 4
(Date:9/16/2014)... WASHINGTON, DC September 14, 2014 A ... provisional side branch (SB) stenting of true coronary ... standard of care. The DKCRUSH-VI clinical trial is ... stenting. , Findings were reported today at ... symposium. Sponsored by the Cardiovascular Research Foundation (CRF), ...
(Date:9/16/2014)... therapy and radiation therapy as part of breast ... women with hormone-receptor positive (HR+) invasive breast cancer. ... Cancer Center, however, shows that combination may not ... disease. , The results, which Fox Chase ... Oncology,s 56th Annual Meeting on Sunday, September 14, ...
(Date:9/16/2014)... that corn absorbs the right balance of nitrogen, phosphorus ... Purdue and Kansas State University study finds. , A ... the U.S. and other regions showed that high yields ... took up key nutrients at specific ratios - nitrogen ... and potassium at a ratio of 1-to-1. These nutrient ...
(Date:9/16/2014)... Seven heroes who have dramatically improved the ... in New York City on November 6 by World ... recognition and funding program that honors individuals serving vulnerable ... the “Nobel Prize for Child Advocates,” this year’s selection ... benefit children in countries around the world dealing with ...
(Date:9/16/2014)... Who:, The Pulmonary Hypertension Association (PHA), ... Children’s Hospital Colorado are hosting Colorado PH in the ... association that works to find ways to prevent and cure ... affects the functioning of the heart and can lead to ... years. , What:, Colorado PH in the Park 2014 ...
Breaking Medicine News(10 mins):Health News:Results of DKCRUSH-VI trial reported at TCT 2014 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:Boosting global corn yields depends on improving nutrient balance 2Health News:Boosting global corn yields depends on improving nutrient balance 3Health News:World of Children® Award Announces 2014 Honorees 2Health News:World of Children® Award Announces 2014 Honorees 3Health News:World of Children® Award Announces 2014 Honorees 4Health News:World of Children® Award Announces 2014 Honorees 5Health News:World of Children® Award Announces 2014 Honorees 6Health News:World of Children® Award Announces 2014 Honorees 7Health News:World of Children® Award Announces 2014 Honorees 8Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2
... A new study shows that estrogen therapy does not ... postmenopausal women, say researchers //.Previous studies have reported an ... dementia. ,A placebo-controlled trial of estrogen or estrogen ... looked at associated risk for dementia. In the estrogen-only ...
... in your 20s could reduce the risk of developing high ... psychological stress with spikes in blood pressure are more likely ... 40s. ,Specialists say assessing blood pressure changes in response ... person’s future risk of high blood pressure. In a large ...
... shows dogs may be able to anticipate seizures in ... dogs in this study was // licking, often ... and “protective" behavior without aggression. In previous studies, owners ... even prevent their seizures. Some breeds of seizure-alerting ...
... patients consume about 40 milligrams of vitamin C daily ... vitamin C may protect against rheumatoid arthritis. ,Researchers ... 45 and 74. Participants' diets were assessed by using ... in two or more joints for at least one ...
... with a number of other side effects. For some people ... through with it may not even get rid of their ... to delivering chemotherapy. ,Perfusion therapy is the most aggressive ... avoid the toxicity to the rest of the body .Blood ...
... might help protect the eyes against a leading cause of ... // men and women it was found that those ... had a 36-percent lower risk of developing age-related maculopathy than ... have linked consumption of antioxidant vitamins and minerals to lower ...
Cached Medicine News:
Scoville cervical disc retractor, self-retaining with ratchet action....
... Image-Line offers superior retractor blade stability ... all cervical spine retraction objectives. The ... rapid and accurate blade size determination. ... accommodates a variety of patients and ...
Small, removable blades, length 178 mm, (7"). Function: tissue retracting....
The High Sensitivity C-Reactive Protein (RCRP) Flex reagent cartridge is an in vitro diagnostic test intended for the quantitative determination of CRP in serum and plasma. This assay is not availabl...
Medicine Products: